Benmelstobart-anlotinib combination superior to pembrolizumab in advanced NSCLC

In participants with programmed cell death-ligand 1 (PD-L1)-positive advanced non-small cell lung cancer (NSCLC), the combination of benmelstobart and anlotinib demonstrated superior efficacy over pembrolizumab monotherapy in the phase 3 CAMPASS trial. Pembrolizumab monotherapy is currently the standard-of-care first-line treatment for patients with NSCLC and high PD-L1 expression, based on earlier trials, such as KEYNOTE-042 (NCT02220894), which showed improved overall survival from pembrolizumab compared with chemotherapy [1]. However, newer combinations may offer even better outcomes. Benmelstobart, a PD-L1 inhibitor, and anlotinib, an anti-angiogenic tyrosine kinase inhibitor, are both approved in China and have shown promising efficacy in the later-line treatment of advanced or metastatic NSCLC [2,3]. The phase 3 CAMPASS trial (NCT04964479...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025